Literature DB >> 32123305

Primary mammary angiosarcomas harbor frequent mutations in KDR and PIK3CA and show evidence of distinct pathogenesis.

Francisco Beca1, Gregor Krings2, Yunn-Yi Chen2, Elizabeth M Hosfield3, Poonam Vohra2, Richard K Sibley1, Megan L Troxell1, Robert B West1, Kimberly H Allison1, Gregory R Bean4.   

Abstract

Angiosarcoma (AS) is the most frequent primary sarcoma of the breast but nevertheless remains uncommon, accounting for <0.05% of breast malignancies. Secondary mammary AS arise following radiation therapy for breast cancer, in contrast to primary AS which occur sporadically. Essentially all show aggressive clinical behavior independent of histologic grade and most are treated by mastectomy. MYC amplification is frequently identified in radiation-induced AS but only rarely in primary mammary AS (PMAS). As a heterogeneous group, AS from various anatomic sites have been shown to harbor recurrent alterations in TP53, MAP kinase pathway genes, and genes involved in angiogenic signaling including KDR (VEGFR2) and PTPRB. In part due to its rarity, the pathogenesis of PMAS has not been fully characterized. In this study, we examined the clinical, pathologic, and genomic features of ten cases of PMAS, including one patient with bilateral disease. Recurrent genomic alterations were identified in KDR (70%), PIK3CA/PIK3R1 (70%), and PTPRB (30%), each at higher frequencies than reported in AS across all sites. Six tumors harbored a KDR p.T771R hotspot mutation, and all seven KDR-mutant cases showed evidence suggestive of biallelism (four with loss of heterozygosity and three with two aberrations). Of the seven tumors with PI3K alterations, six harbored pathogenic mutations other than in the canonical PIK3CA residues which are most frequent in breast cancer. Three AS were hypermutated (≥10 mutations/megabase (Mb)); hypermutation was seen concurrent with KDR or PIK3CA mutations. The patient with bilateral disease demonstrated shared alterations, indicative of contralateral metastasis. No MYC or TP53 aberrations were detected in this series. Immunohistochemistry for VEGFR2 was unable to discriminate between KDR-mutant tumors and benign vascular lesions of the breast. These findings highlight the underrecognized frequency of KDR and PIK3CA mutation in PMAS, and a significant subset with hypermutation, suggesting a pathogenesis distinct from other AS.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32123305     DOI: 10.1038/s41379-020-0511-6

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  72 in total

Review 1.  Angiosarcoma.

Authors:  Robin J Young; Nicola J Brown; Malcolm W Reed; David Hughes; Penella J Woll
Journal:  Lancet Oncol       Date:  2010-05-25       Impact factor: 41.316

2.  Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO).

Authors:  Isabelle Ray-Coquard; Antoine Italiano; Emmanuelle Bompas; Axel Le Cesne; Yves-Marie Robin; Christine Chevreau; Jacques-Olivier Bay; Guilhem Bousquet; Sophie Piperno-Neumann; Nicolas Isambert; Laurent Lemaitre; Charles Fournier; Eric Gauthier; Olivier Collard; Didier Cupissol; Stéphanie Clisant; Jean-Yves Blay; Nicolas Penel
Journal:  Oncologist       Date:  2012-01-27

Review 3.  Advances in sarcoma genomics and new therapeutic targets.

Authors:  Barry S Taylor; Jordi Barretina; Robert G Maki; Cristina R Antonescu; Samuel Singer; Marc Ladanyi
Journal:  Nat Rev Cancer       Date:  2011-07-14       Impact factor: 60.716

4.  Angiosarcoma: clinical and molecular insights.

Authors:  Guy Lahat; Asha R Dhuka; Hen Hallevi; Lianchun Xiao; Changye Zou; Kerrington D Smith; Thuy L Phung; Raphael E Pollock; Robert Benjamin; Kelly K Hunt; Alexander J Lazar; Dina Lev
Journal:  Ann Surg       Date:  2010-06       Impact factor: 12.969

5.  Irradiation-induced angiosarcoma and anti-angiogenic therapy: a therapeutic hope?

Authors:  Amalia Azzariti; Letizia Porcelli; Anita Mangia; Concetta Saponaro; Anna E Quatrale; Ondina S Popescu; Sabino Strippoli; Gianni Simone; Angelo Paradiso; Michele Guida
Journal:  Exp Cell Res       Date:  2013-12-31       Impact factor: 3.905

Review 6.  Vascular proliferations of the breast.

Authors:  C Brodie; E Provenzano
Journal:  Histopathology       Date:  2008-01       Impact factor: 5.087

7.  Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases.

Authors:  J Fayette; E Martin; S Piperno-Neumann; A Le Cesne; C Robert; S Bonvalot; D Ranchère; P Pouillart; J M Coindre; J Y Blay
Journal:  Ann Oncol       Date:  2007-10-31       Impact factor: 32.976

8.  Prognostic factors in angiosarcoma: a multivariate analysis of 55 cases.

Authors:  N Naka; M Ohsawa; Y Tomita; H Kanno; A Uchida; A Myoui; K Aozasa
Journal:  J Surg Oncol       Date:  1996-03       Impact factor: 3.454

Review 9.  Angiosarcoma. A report of 67 patients and a review of the literature.

Authors:  R J Mark; J C Poen; L M Tran; Y S Fu; G F Juillard
Journal:  Cancer       Date:  1996-06-01       Impact factor: 6.860

10.  Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series.

Authors:  Kwai Han Yoo; Hyo Song Kim; Su Jin Lee; Se Hoon Park; Sung Joo Kim; Soo Hee Kim; Yoon La Choi; Kyoo-Ho Shin; Yong Jin Cho; Jeeyun Lee; Sun Young Rha
Journal:  BMC Cancer       Date:  2015-03-19       Impact factor: 4.430

View more
  4 in total

Review 1.  Angiosarcomas: histology, immunohistochemistry and molecular insights with implications for differential diagnosis.

Authors:  Isidro Machado; Francisco Giner; Javier Lavernia; Julia Cruz; Víctor Traves; Celia Requena; Beatriz Llombart; José Antonio López-Guerrero; Antonio Llombart-Bosch
Journal:  Histol Histopathol       Date:  2020-09-04       Impact factor: 2.303

2.  Genomically Complex Human Angiosarcoma and Canine Hemangiosarcoma Establish Convergent Angiogenic Transcriptional Programs Driven by Novel Gene Fusions.

Authors:  Jong Hyuk Kim; Kate Megquier; Rachael Thomas; Aaron L Sarver; Jung Min Song; Yoon Tae Kim; Nuojin Cheng; Ashley J Schulte; Michael A Linden; Paari Murugan; LeAnn Oseth; Colleen L Forster; Ingegerd Elvers; Ross Swofford; Jason Turner-Maier; Elinor K Karlsson; Matthew Breen; Kerstin Lindblad-Toh; Jaime F Modiano
Journal:  Mol Cancer Res       Date:  2021-03-01       Impact factor: 6.333

Review 3.  Optimal Clinical Management and the Molecular Biology of Angiosarcomas.

Authors:  Tom Wei-Wu Chen; Jessica Burns; Robin L Jones; Paul H Huang
Journal:  Cancers (Basel)       Date:  2020-11-10       Impact factor: 6.639

4.  In vitro anticancer effects of alpelisib against PIK3CA‑mutated canine hemangiosarcoma cell lines.

Authors:  Marika Maeda; Kazuhiko Ochiai; Masaki Michishita; Masami Morimatsu; Hiroki Sakai; Nayuta Kinoshita; Motoharu Sakaue; Eri Onozawa; Daigo Azakami; Masami Yamamoto; Katsumi Ishioka; Takuya Sadahira; Masami Watanabe; Yoshikazu Tanaka
Journal:  Oncol Rep       Date:  2022-03-02       Impact factor: 3.906

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.